{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:44:59Z","timestamp":1791067499452,"version":"4.1.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.pharmthera.2010.06.001","type":"journal-article","created":{"date-parts":[[2010,6,21]],"date-time":"2010-06-21T01:02:27Z","timestamp":1277082147000},"page":"106-118","source":"Crossref","is-referenced-by-count":43,"title":["Cyclosporin A and atherosclerosis \u2014 Cellular pathways in atherogenesis"],"prefix":"10.1016","volume":"128","author":[{"given":"Maaike","family":"Kockx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Jessup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Kritharides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/hep.510250433","article-title":"Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"25","author":"al Rayyes","year":"1997","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.06.001_bib2","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2009-04-211417","article-title":"Apolipoprotein-mediated lipid antigen presentation in B cells provides a pathway for innate help by NKT cells","volume":"114","author":"Allan","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/01.ATV.19.7.1687","article-title":"Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits: T lymphocyte-mediated immune responses not involved in balloon injury-induced neointimal proliferation","volume":"19","author":"Andersen","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib4","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0021-9150(97)00123-8","article-title":"Effect of cyclosporine during initiation of transplant arteriosclerosis. An ultrastructural study in the aorta-transplanted rabbit","volume":"133","author":"Andersen","year":"1997","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2009.07.002","article-title":"Adaptive immunity and atherosclerosis","volume":"134","author":"Andersson","year":"2010","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00007890-199409000-00005","article-title":"Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients","volume":"58","author":"Apanay","year":"1994","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0021-9150(93)90037-U","article-title":"Elevated high density lipoprotein concentrations in heart transplant recipients are related to impaired plasma cholesteryl ester transfer and hepatic lipase activity","volume":"103","author":"Atger","year":"1993","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/PL00000199","article-title":"Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production","volume":"49","author":"Attur","year":"2000","journal-title":"Inflamm Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib9","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1046\/j.1523-1755.1999.00481.x","article-title":"Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells","volume":"55","author":"Avdonin","year":"1999","journal-title":"Kidney Int"},{"issue":"42","key":"10.1016\/j.pharmthera.2010.06.001_bib10","doi-asserted-by":"crossref","first-page":"26253","DOI":"10.1074\/jbc.272.42.26253","article-title":"Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport","volume":"272","author":"Babiker","year":"1997","journal-title":"J Biol Chem"},{"issue":"24","key":"10.1016\/j.pharmthera.2010.06.001_bib11","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00018-006-6215-3","article-title":"Immunophilins: for the love of proteins","volume":"63","author":"Barik","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib12","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1172\/JCI118271","article-title":"Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice","volume":"96","author":"Bellosta","year":"1995","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib13","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/lt.21588","article-title":"Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression","volume":"14","author":"Bianchi","year":"2008","journal-title":"Liver Transpl"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.06.001_bib14","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1073\/pnas.91.18.8592","article-title":"Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages","volume":"91","author":"Bjorkhem","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0065-2571(94)90023-X","article-title":"ATP-dependent export pumps and their inhibition by cyclosporins","volume":"34","author":"Bohme","year":"1994","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cbi.2010.02.029","article-title":"Long-term cyclosporine treatment in non-transplanted rats and metabolic risk factors of vascular diseases","volume":"185","author":"Bohmer","year":"2010","journal-title":"Chem Biol Interact"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0031-6997(25)00027-4","article-title":"Pharmacology of cyclosporine (sandimmune). I. Introduction","volume":"41","author":"Borel","year":"1990","journal-title":"Pharmacol Rev"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.06.001_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/eji.1830110812","article-title":"Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2","volume":"11","author":"Bunjes","year":"1981","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib19","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/00007890-199706150-00006","article-title":"Cholestatic effects of cyclosporine in the rat","volume":"63","author":"Chan","year":"1997","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib20","first-page":"133","article-title":"Modulation of the inhibition of respiratory burst in mouse macrophages by cyclosporin A: effect of in vivo treatment, glucocorticoids and the state of activation of cells","volume":"72","author":"Chiara","year":"1991","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib21","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/S0041-1345(99)00364-4","article-title":"Fatty acid composition in low-density lipoproteins from renal transplant recipients","volume":"31","author":"Cofan","year":"1999","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib22","first-page":"476","article-title":"Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity","volume":"84","author":"Conde","year":"1995","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2003-08-2804","article-title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions","volume":"103","author":"Coppinger","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bjp.0703878","article-title":"Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment","volume":"132","author":"Cottet-Maire","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib25","first-page":"357","article-title":"Inhibition by cyclosporin A of a Ca2+-dependent pore in heart mitochondria activated by inorganic phosphate and oxidative stress","volume":"255","author":"Crompton","year":"1988","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1023\/B:DDAS.0000011598.15105.58","article-title":"Everolimus\/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats","volume":"49","author":"Deters","year":"2004","journal-title":"Dig Dis Sci"},{"issue":"7\u20138","key":"10.1016\/j.pharmthera.2010.06.001_bib27","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0891-5849(98)00320-7","article-title":"Cyclosporin A does not increase the oxidative susceptibility of low density lipoprotein in vitro","volume":"26","author":"Devaraj","year":"1999","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib28","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00007890-198306000-00014","article-title":"Alterations in rat pulmonary macrophage function by the immunosuppressive agents cyclosporine, azathioprine, and prednisolone","volume":"35","author":"Drath","year":"1983","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0021-9150(95)05539-9","article-title":"Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit","volume":"116","author":"Drew","year":"1995","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib30","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1095\/biolreprod.107.063503","article-title":"Cyclosporin A promotes growth and invasiveness in vitro of human first-trimester trophoblast cells via MAPK3\/MAPK1-mediated AP1 and Ca2+\/calcineurin\/NFAT signaling pathways","volume":"78","author":"Du","year":"2008","journal-title":"Biol Reprod"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib31","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.4049\/jimmunol.0801772","article-title":"Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C\/EBP family: implication for unfolded protein response","volume":"182","author":"Du","year":"2009","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib32","first-page":"1906","article-title":"Accelerated atherosclerosis in hyperlipidemic C57BL\/6 mice treated with cyclosporin A","volume":"142","author":"Emeson","year":"1993","journal-title":"Am J Pathol"},{"issue":"4937","key":"10.1016\/j.pharmthera.2010.06.001_bib33","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1126\/science.2595372","article-title":"Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation","volume":"246","author":"Emmel","year":"1989","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/0735-1097(91)90748-X","article-title":"Lipoprotein(a) and apolipoprotein changes after cardiac transplantation","volume":"18","author":"Farmer","year":"1991","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1432-2277.1998.tb00789.x","article-title":"Lipid abnormalities in stable liver transplant recipients\u2014effects of cyclosporin, tacrolimus, and steroids","volume":"11","author":"Fernandez-Miranda","year":"1998","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib36","first-page":"403","article-title":"Vascular effects of cyclosporine A in vivo and in vitro","volume":"137","author":"Ferns","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.1993.tb17141.x","article-title":"Cyclosporins. Structure\u2013activity relationships","volume":"696","author":"Fliri","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib38","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/j.1460-2075.1994.tb06329.x","article-title":"Calcineurin acts in synergy with PMA to inactivate I kappa B\/MAD3, an inhibitor of NF-kappa B","volume":"13","author":"Frantz","year":"1994","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0006-2952(92)90374-R","article-title":"Inhibition of biliary lipid and protein secretion by cyclosporine A in the rat","volume":"44","author":"Galan","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib40","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev.immunol.021908.132620","article-title":"Immune and inflammatory mechanisms of atherosclerosis (*)","volume":"27","author":"Galkina","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2010.06.001_bib41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09629350020008682","article-title":"Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells","volume":"9","author":"Garcia","year":"2000","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1124\/jpet.109.163949","article-title":"Cyclosporine up-regulates Kruppel-like factor-4 (KLF4) in vascular smooth muscle cells and drives phenotypic modulation in vivo","volume":"333","author":"Garvey","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib43","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ki.1996.69","article-title":"Increased low density lipoprotein oxidation in stable kidney transplant recipients","volume":"49","author":"Ghanem","year":"1996","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cvr\/cvp063","article-title":"Inhibition of mitochondrial permeability transition pore opening: translation to patients","volume":"83","author":"Gomez","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib45","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1742-7843.2007.00066.x","article-title":"Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase","volume":"100","author":"Gueguen","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.intimp.2008.07.012","article-title":"Calcineurin inhibitors down-regulate iNOS expression by destabilizing mRNA","volume":"9","author":"Hamalainen","year":"2009","journal-title":"Int Immunopharmacol"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2010.06.001_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(02)01947-7","article-title":"Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines","volume":"448","author":"Hamalainen","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib48","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nri1882","article-title":"The immune response in atherosclerosis: a double-edged sword","volume":"6","author":"Hansson","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib49","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1161\/01.CIR.91.2.386","article-title":"Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model","volume":"91","author":"Hirozane","year":"1995","journal-title":"Circulation"},{"issue":"3 Pt 2","key":"10.1016\/j.pharmthera.2010.06.001_bib50","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"issue":"9374","key":"10.1016\/j.pharmthera.2010.06.001_bib51","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/abio.1994.1481","article-title":"Comparative binding studies of cyclophilins to cyclosporin A and derivatives by fluorescence measurements","volume":"222","author":"Husi","year":"1994","journal-title":"Anal Biochem"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.ATV.0000196747.79349.d1","article-title":"Role of cAMP response element binding protein in cardiovascular remodeling: good, bad, or both?","volume":"26","author":"Ichiki","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"issue":"46","key":"10.1016\/j.pharmthera.2010.06.001_bib55","doi-asserted-by":"crossref","first-page":"31584","DOI":"10.1074\/jbc.M802535200","article-title":"The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens","volume":"283","author":"Ishikawa","year":"2008","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.06.001_bib56","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1074\/jbc.M103878200","article-title":"Apolipoprotein A-I induces translocation of cholesterol, phospholipid, and caveolin-1 to cytosol in rat astrocytes","volume":"277","author":"Ito","year":"2002","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib57","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6","article-title":"Immunophilins: switched on protein binding domains?","volume":"20","author":"Ivery","year":"2000","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib58","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.febslet.2009.11.031","article-title":"Differential functions of genes regulated by VEGF-NFATc1 signaling pathway in the migration of pulmonary valve endothelial cells","volume":"584","author":"Jang","year":"2010","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib59","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study","volume":"4","author":"Jardine","year":"2004","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib60","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1124\/jpet.109.153213","article-title":"Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases","volume":"330","author":"Javadov","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib61","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0022-2275(20)30106-1","article-title":"25R, 26-Hydroxycholesterol revisited: synthesis, metabolism, and biologic roles","volume":"43","author":"Javitt","year":"2002","journal-title":"J Lipid Res"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib62","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/01.ATV.0000130664.51010.28","article-title":"Cyclophilin A is a proinflammatory cytokine that activates endothelial cells","volume":"24","author":"Jin","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib63","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1073\/pnas.85.7.2303","article-title":"Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury","volume":"85","author":"Jonasson","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib64","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.4049\/jimmunol.179.7.4598","article-title":"Calcineurin negatively regulates TLR-mediated activation pathways","volume":"179","author":"Kang","year":"2007","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib65","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.ATV.14.5.780","article-title":"Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2","volume":"14","author":"Kaptein","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib66","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1194\/jlr.M003145","article-title":"Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+ dependent-calcineurin signaling","volume":"51","author":"Karwatsky","year":"2010","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib67","first-page":"176","article-title":"Cardiovascular disease after renal transplantation","volume":"20","author":"Kasiske","year":"2000","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib68","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neuropharm.2006.04.020","article-title":"Cyclosporin A inhibits apolipoprotein A-I-induced early events in cellular cholesterol homeostasis in rat astrocytes","volume":"51","author":"Kheirollah","year":"2006","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib69","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/S0002-9440(10)63715-7","article-title":"Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction","volume":"164","author":"Kim","year":"2004","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/08860220600778878","article-title":"A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients","volume":"28","author":"Kimak","year":"2006","journal-title":"Ren Fail"},{"issue":"36","key":"10.1016\/j.pharmthera.2010.06.001_bib71","doi-asserted-by":"crossref","first-page":"24144","DOI":"10.1074\/jbc.M109.032615","article-title":"Cyclosporin A decreases apolipoprotein E secretion from human macrophages via a protein phosphatase 2B-dependent and ATP-binding cassette transporter A1 (ABCA1)-independent pathway","volume":"284","author":"Kockx","year":"2009","journal-title":"J Biol Chem"},{"issue":"33","key":"10.1016\/j.pharmthera.2010.06.001_bib72","doi-asserted-by":"crossref","first-page":"29669","DOI":"10.1074\/jbc.M204519200","article-title":"Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A","volume":"277","author":"Kou","year":"2002","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.06.001_bib73","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/10715760500104009","article-title":"Cyclosporin A generates superoxide in smooth muscle cells","volume":"39","author":"Krauskopf","year":"2005","journal-title":"Free Radic Res"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib74","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0021-9150(02)00011-4","article-title":"The use of antioxidant supplements in coronary heart disease","volume":"164","author":"Kritharides","year":"2002","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/PL00005073","article-title":"Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells","volume":"356","author":"Kruger","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1006\/bbrc.1995.2642","article-title":"Interleukin 1 beta-induced expression of nitric oxide synthase in rat renal mesangial cells is suppressed by cyclosporin A","volume":"216","author":"Kunz","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.06.001_bib77","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1097\/00007890-199405270-00014","article-title":"Relation of cyclosporine blood levels to adverse effects on lipoproteins","volume":"57","author":"Kuster","year":"1994","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib78","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1161\/01.ATV.0000144811.94581.52","article-title":"Cyclosporin A traps ABCA1 at the plasma membrane and inhibits ABCA1-mediated lipid efflux to apolipoprotein A-I","volume":"24","author":"Le Goff","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib79","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1074\/jbc.272.6.3137","article-title":"Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway","volume":"272","author":"Lehmann","year":"1997","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0301-472X(02)00777-4","article-title":"NFkappaB-dependent signaling pathways","volume":"30","author":"Li","year":"2002","journal-title":"Exp Hematol"},{"issue":"6917","key":"10.1016\/j.pharmthera.2010.06.001_bib81","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.pharmthera.2010.06.001_bib82","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.1074\/jbc.M500322200","article-title":"Blockade of nuclear factor of activated T cells activation signaling suppresses balloon injury-induced neointima formation in a rat carotid artery model","volume":"280","author":"Liu","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib83","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1476-5381.1996.tb15482.x","article-title":"Effect of cyclosporin A and analogues on cytosolic calcium and vasoconstriction: possible lack of relationship to immunosuppressive activity","volume":"118","author":"Lo Russo","year":"1996","journal-title":"Br J Pharmacol"},{"issue":"23","key":"10.1016\/j.pharmthera.2010.06.001_bib84","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.1016\/S0021-9258(18)98546-7","article-title":"Cyclosporin A inhibits an initial step in folding of transferrin within the endoplasmic reticulum","volume":"266","author":"Lodish","year":"1991","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib85","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0026-0495(93)90232-D","article-title":"Low-density lipoprotein metabolism in rats treated with cyclosporine","volume":"42","author":"Lopez-Miranda","year":"1993","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00109-007-0267-1","article-title":"Apolipoprotein A-I but not high-density lipoproteins are internalised by RAW macrophages: roles of ATP-binding cassette transporter A1 and scavenger receptor BI","volume":"86","author":"Lorenzi","year":"2008","journal-title":"J Mol Med"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib87","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clim.2009.07.016","article-title":"Innate immune signals in atherosclerosis","volume":"134","author":"Lundberg","year":"2010","journal-title":"Clin Immunol"},{"issue":"47","key":"10.1016\/j.pharmthera.2010.06.001_bib88","doi-asserted-by":"crossref","first-page":"48794","DOI":"10.1074\/jbc.M313897200","article-title":"Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae","volume":"279","author":"Lungu","year":"2004","journal-title":"J Biol Chem"},{"issue":"18","key":"10.1016\/j.pharmthera.2010.06.001_bib89","doi-asserted-by":"crossref","first-page":"13351","DOI":"10.1074\/jbc.M611522200","article-title":"Cyclosporin A and FK506 inhibit IL-12p40 production through the calmodulin\/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells","volume":"282","author":"Ma","year":"2007","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib90","doi-asserted-by":"crossref","first-page":"7328","DOI":"10.1074\/jbc.272.11.7328","article-title":"Studies on intracellular translocation of apolipoprotein B in a permeabilized HepG2 system","volume":"272","author":"Macri","year":"1997","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.pharmthera.2010.06.001_bib91","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1128\/MCB.00541-09","article-title":"An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2","volume":"29","author":"Maitra","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib92","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/anie.200904529","article-title":"A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins","volume":"49","author":"Malesevic","year":"2010","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib93","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1152\/physrev.1996.76.3.631","article-title":"Cellular functions of immunophilins","volume":"76","author":"Marks","year":"1996","journal-title":"Physiol Rev"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib94","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/embo-reports\/kvd090","article-title":"Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation","volume":"1","author":"Matsuda","year":"2000","journal-title":"EMBO Rep"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.06.001_bib95","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/01.TP.0000090393.75600.32","article-title":"Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice","volume":"76","author":"Matsumoto","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib96","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.transproceed.2004.05.073","article-title":"Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels","volume":"36","author":"Mercanoglu","year":"2004","journal-title":"Transplant Proc"},{"issue":"13","key":"10.1016\/j.pharmthera.2010.06.001_bib97","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2174\/138161210791051022","article-title":"HDL: key molecule in cholesterol efflux and the prevention of atherosclerosis","volume":"16","author":"Meurs","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.pharmthera.2010.06.001_bib98","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.tp.0000188177.21406.97","article-title":"Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice","volume":"81","author":"Moghadasian","year":"2006","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib100","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.febslet.2006.04.039","article-title":"The chaperone function of cyclophilin 40 maps to a cleft between the prolyl isomerase and tetratricopeptide repeat domains","volume":"580","author":"Mok","year":"2006","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib101","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.cardiores.2003.11.038","article-title":"Nuclear factor kappaB: a potential therapeutic target in atherosclerosis and thrombosis","volume":"61","author":"Monaco","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib102","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diacare.25.3.583","article-title":"Posttransplantation diabetes: a systematic review of the literature","volume":"25","author":"Montori","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib103","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0168-8278(98)80180-3","article-title":"Inhibition of biliary glutathione secretion by cyclosporine A in the rat: possible mechanisms and role in the cholestasis induced by the drug","volume":"29","author":"Moran","year":"1998","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib104","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/01.ATV.0000094234.60166.78","article-title":"Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells","volume":"23","author":"Murakami","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.06.001_bib105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mam.2004.09.003","article-title":"The role of nitric oxide in cardiovascular diseases","volume":"26","author":"Naseem","year":"2005","journal-title":"Mol Aspects Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib106","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1074\/jbc.275.5.3075","article-title":"Transcriptional induction of endothelial nitric oxide gene by cyclosporine A. A role for activator protein-1","volume":"275","author":"Navarro-Antolin","year":"2000","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib107","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.tp.0000235527.81917.fe","article-title":"Cardiovascular complications after renal transplantation and their prevention","volume":"82","author":"Ojo","year":"2006","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib108","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00075198-200112000-00003","article-title":"Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies","volume":"7","author":"Olyaei","year":"2001","journal-title":"Curr Opin Crit Care"},{"issue":"12","key":"10.1016\/j.pharmthera.2010.06.001_bib109","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.4049\/jimmunol.136.12.4348","article-title":"Cyclosporine inhibits macrophage-mediated antigen presentation","volume":"136","author":"Palay","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/978-1-60327-029-8_24","article-title":"Oxidized low-density lipoprotein","volume":"610","author":"Parthasarathy","year":"2010","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib111","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.atherosclerosis.2007.08.025","article-title":"Cyclophilin A differentially activates monocytes and endothelial cells: role of purity, activity, and endotoxin contamination in commercial preparations","volume":"197","author":"Payeli","year":"2008","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1056\/NEJMoa071142","article-title":"Effect of cyclosporine on reperfusion injury in acute myocardial infarction","volume":"359","author":"Piot","year":"2008","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2010.06.001_bib113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/bj2750501","article-title":"Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis","volume":"275","author":"Princen","year":"1991","journal-title":"Biochem J"},{"issue":"38","key":"10.1016\/j.pharmthera.2010.06.001_bib114","doi-asserted-by":"crossref","first-page":"35605","DOI":"10.1074\/jbc.M205826200","article-title":"Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS. Paradoxical proinflammatory effect on the microvascular endothelium","volume":"277","author":"Rafiee","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/ecam\/nep225","article-title":"Attenuated combined action of cyclosporine A and hyperlipidemia on atherogenesis in rabbits by thymoquinone","author":"Ragheb","year":"2009","journal-title":"Evid Based Complement Alternat Med"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib116","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.transproceed.2007.03.035","article-title":"Hyperlipidemia after renal transplantation and its relation to graft and patient survival","volume":"39","author":"Ramezani","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib117","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.febslet.2010.02.022","article-title":"Signal transduction to the permeability transition pore","volume":"584","author":"Rasola","year":"2010","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib118","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/hep.510240325","article-title":"Cyclosporine inhibits catabolism of low-density lipoproteins in HepG2 cells by about 25%","volume":"24","author":"Rayyes","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.pharmthera.2010.06.001_bib119","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/BF01062550","article-title":"On the dose dependency of cyclosporin A absorption and disposition in healthy volunteers","volume":"16","author":"Reymond","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007893.pub2","article-title":"Effect of cyclosporine on blood pressure","volume":"1","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib121","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.molcel.2009.01.030","article-title":"A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants","volume":"33","author":"Rodriguez","year":"2009","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib122","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI118174","article-title":"Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity","volume":"96","author":"Roselaar","year":"1995","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib123","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nm.1958","article-title":"Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms","volume":"15","author":"Satoh","year":"2009","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib124","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/01.RES.0000118250.67032.5E","article-title":"Calcineurin promotes the expression of monocyte chemoattractant protein-1 in vascular myocytes and mediates vascular inflammation","volume":"94","author":"Satonaka","year":"2004","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2010.06.001_bib125","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1160\/TH08-12-0830","article-title":"The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation","volume":"102","author":"Schweighofer","year":"2009","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib126","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0021-9150(00)00654-7","article-title":"Transcriptional regulation of the human sterol 27-hydroxylase gene (CYP27) and promoter mapping","volume":"156","author":"Segev","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.atherosclerosis.2009.08.029","article-title":"EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation","volume":"209","author":"Seizer","year":"2010","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.06.001_bib128","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1073\/pnas.89.8.3511","article-title":"Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages","volume":"89","author":"Sherry","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"10.1016\/j.pharmthera.2010.06.001_bib129","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0024-3205(99)00089-2","article-title":"Modulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase activities by steroids and physiological conditions in hamster","volume":"64","author":"Souidi","year":"1999","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.pharmthera.2010.06.001_bib130","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-2275(20)36963-7","article-title":"Regulatory effects of individual n-6 and n-3 polyunsaturated fatty acids on LDL transport in the rat","volume":"34","author":"Spady","year":"1993","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0021-9258(17)35315-2","article-title":"Cyclosporin A slows collagen triple-helix formation in vivo: indirect evidence for a physiologic role of peptidyl-prolyl cis-trans-isomerase","volume":"266","author":"Steinmann","year":"1991","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib132","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","article-title":"Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver","volume":"118","author":"Stieger","year":"2000","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.pharmthera.2010.06.001_bib133","first-page":"392","article-title":"Cholesterol precursor concentration in plasma from patients with chronic renal failure or kidney grafts","volume":"43","author":"Sutherland","year":"1995","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib134","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.ATV.14.5.734","article-title":"Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts","volume":"14","author":"Tanaka","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol Rev"},{"issue":"10","key":"10.1016\/j.pharmthera.2010.06.001_bib136","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1089\/ars.2008.2027","article-title":"Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities","volume":"10","author":"Thomas","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2010.06.001_bib137","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2008.03.026","article-title":"Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma","volume":"358","author":"Tory","year":"2008","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.pharmthera.2010.06.001_bib138","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1074\/jbc.M109278200","article-title":"Cholesteryl ester is transported from caveolae to internal membranes as part of a caveolin-annexin II lipid\u2013protein complex","volume":"277","author":"Uittenbogaard","year":"2002","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.pharmthera.2010.06.001_bib139","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1074\/jbc.273.11.6525","article-title":"Characterization of a cytosolic heat-shock protein\u2212caveolin chaperone complex. Involvement in cholesterol trafficking","volume":"273","author":"Uittenbogaard","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmthera.2010.06.001_bib140","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/ki.1997.221","article-title":"Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients","volume":"51","author":"van den Dorpel","year":"1997","journal-title":"Kidney Int"},{"issue":"7060","key":"10.1016\/j.pharmthera.2010.06.001_bib141","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/nature04001","article-title":"Apolipoprotein-mediated pathways of lipid antigen presentation","volume":"437","author":"van den Elzen","year":"2005","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib142","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0022-3565(24)39134-7","article-title":"Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions","volume":"294","author":"Vaziri","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib143","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00007890-199707150-00005","article-title":"Allo- and autotransplantation of carotid artery\u2014a new model of chronic graft vessel disease: evaluation by magnetic resonance imaging and histology","volume":"64","author":"Wehr","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.pharmthera.2010.06.001_bib144","first-page":"301","article-title":"Cyclosporine: intrinsic binding energies to interpret structure\u2013activity relationships","volume":"291","author":"Wenger","year":"1989","journal-title":"Prog Clin Biol Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib145","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00007890-198507000-00012","article-title":"The impaired ability of human monocytes to stimulate autologous and allogeneic mixed lymphocyte reactions after exposure to cyclosporine. Associated alterations of HLA-DR expression and physical characteristics of monocytes","volume":"40","author":"Whisler","year":"1985","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.pharmthera.2010.06.001_bib146","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-2275(20)37646-X","article-title":"Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells","volume":"37","author":"Winegar","year":"1996","journal-title":"J Lipid Res"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2010.06.001_bib147","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1042\/bj3360287","article-title":"Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition","volume":"336","author":"Woodfield","year":"1998","journal-title":"Biochem J"},{"issue":"6 Pt 1","key":"10.1016\/j.pharmthera.2010.06.001_bib148","first-page":"E1087","article-title":"Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2","volume":"277","author":"Wu","year":"1999","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib149","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1527-3466.2007.00011.x","article-title":"Therapeutic potential of VIVIT, a selective peptide inhibitor of nuclear factor of activated T cells, in cardiovascular disorders","volume":"25","author":"Yu","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"issue":"2","key":"10.1016\/j.pharmthera.2010.06.001_bib150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1677\/jme.1.02052","article-title":"Cyclosporin A inhibits apolipoprotein AI gene expression","volume":"37","author":"Zheng","year":"2006","journal-title":"J Mol Endocrinol"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810001191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T02:57:31Z","timestamp":1740193051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725810001191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0163725810001191"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2010.06.001","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}